Geoffrey Oxnard, MD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

MD, University of Chicago
AB, Harvard University

Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.

Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clin Cancer Res. 2023 Sep 01; 29(17):3340-3351. PMID: 37379430
  2. Rotow J, Patel JD, Hanley MP, Yu H, Awad M, Goldman JW, Nechushtan H, Scheffler M, Kuo CS, Rajappa S, Harada G, Clifford S, Santucci A, Silva L, Tupper R, Oxnard GR, Kherani J, Drilon A. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers. Clin Cancer Res. 2023 Aug 15; 29(16):2979-2987. PMID: 36996322
  3. Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, Ebrahimi H, Pal S, Dorff T, Agarwal N, Mahal BA, Oxnard GR, Hwang J, Antonarakis ES. Unique spectrum of activating BRAF alterations in prostate cancer. Clin Cancer Res. 2023 Jul 21. PMID: 37477913
  4. Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, Ross JS, Huang RSP, Schrock AB, Oxnard GR, Chakrabarti S, Mahipal A. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. JCO Precis Oncol. 2023 Jul; 7:e2300092. PMID: 37410975
  5. Huang RSP, Graf RP, Oxnard GR. Not all TMB assays are the same: Clinical validity of robust algorithmic germline filtering. Cancer Cell. 2023 May 08; 41(5):819-820. PMID: 37059103
  6. Quintanilha JCF, Graf RP, Oxnard GR. BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer. Oncologist. 2023 Mar 17; 28(3):e171-e174. PMID: 36779536; PMCID: PMC10020799; DOI: 10.1093/oncolo/oyac265;
  7. Assaf ZJF, Zou W, Fine AD, Socinski MA, Young A, Lipson D, Freidin JF, Kennedy M, Polisecki E, Nishio M, Fabrizio D, Oxnard GR, Cummings C, Rode A, Reck M, Patil NS, Lee M, Shames DS, Schulze K. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023 Apr; 29(4):859-868. PMID: 36928816; PMCID: PMC10115641; DOI: 10.1038/s41591-023-02226-6;
  8. Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, Sivakumar S, Lee JK, Fisher V, Oxnard GR, Tukachinsky H. Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma. Clin Cancer Res. 2023 Mar 14; 29(6):1056-1067. PMID: 36321996; PMCID: PMC10011882; DOI: 10.1158/1078-0432.CCR-22-2115;
  9. Mata DA, Harries L, Williams EA, Hiemenz MC, Decker B, Tse JY, Janovitz T, Ferguson DC, Speece IA, Margolis ML, Mathews B, Fedorchak K, Killian JK, Xiao J, Tolba KA, Ramkissoon S, Vergilio JA, Elvin JA, Oxnard GR, Ross JS, Huang RSP. Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer. Arch Pathol Lab Med. 2023 Mar 01; 147(3):338-347. PMID: 35771716
  10. Parimi V, Tolba K, Danziger N, Kuang Z, Sun D, Lin DI, Hiemenz MC, Schrock AB, Ross JS, Oxnard GR, Huang RSP. Genomic landscape of 891 RET fusions detected across diverse solid tumor types. NPJ Precis Oncol. 2023 Jan 23; 7(1):10. PMID: 36690680; PMCID: PMC9870857; DOI: 10.1038/s41698-023-00347-2;
Showing 10 of 185 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 185 publications over 20 distinct years, with a maximum of 28 publications in 2022

Contact for Mentoring:

820 Harrison Ave Boston MA
Google Map

Oxnard's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department